Developing Symptom Lists for People with Cancer Treated with Targeted Therapies

the EORTC Quality of Life Group

doi:10.1007/s11523-020-00769-z

Developing Symptom Lists for People with Cancer Treated with Targeted Therapies

the EORTC Quality of Life Group

University of Southampton
Swansea University
Italian Group for Adult Hematologic Disease (GIMEMA), Rome, Italy
Amsterdam UMC - University of Amsterdam
University of Aberdeen
Poole Hospital NHS Trust
Martin Luther University Halle-Wittenberg
European Organisation for Research and Treatment of Cancer Data Center
Royal Marsden NHS Foundation Trust
Université PSL
Technische Universität Dresden
Complejo Hospitalario de Navarra, Navarra, Spain
Ministry of Health, Cyprus
The Christie NHS Foundation Trust
Maria Sklodowska-Curie Institute of Oncology
National and Kapodistrian University of Athens
University Hospital Centre Rijeka
Faculty of Health and Sport Sciences, University of Adger, Agder, Norway
Sørlandet Hospital, Kristiansand, Norway
Bank of Cyprus Oncology Centre

Research output: Contribution to journal › Article › Academic › peer-review

13 Downloads (Pure)

Abstract

Background: Targeted therapies (TTs) have revolutionised cancer treatment with their enhanced specificity of action. Compared with conventional therapies, TTs are delivered over a longer period and often have unusual symptom profiles. Patient-reported outcome measures such as symptom side-effect lists need to be developed in a time-efficient manner to enable a rapid and full evaluation of new treatments and effective clinical management Objective: The aim of this study was to develop a set of TT-related symptoms and identify the optimal method for developing symptom lists. Patients and Methods: Symptoms from TT treatment in the context of Chronic Myeloid Leukaemia (CML), HER2-positive breast cancer, or Gastrointestinal Stromal Tumours (GIST) were identified through literature reviews, interviews with healthcare professionals (HCPs) and patients, and patient focus groups. The symptom set was then pilot tested in patients across the three cancer diagnoses: The number of items derived from each source (literature, patients, or HCPs) were compared. Results: A total of 316 patients and 86 HCPs from 16 countries participated. An initial set of 209 symptoms was reduced to 61 covering 12 symptom categories. Patient interviews made the greatest contribution to the item set. Conclusions: Symptom lists should be created based on input from patients. The item set described will be applicable to the assessment of new TTs, and in monitoring treatment.

Original language	English
Pages (from-to)	95-107
Number of pages	13
Journal	Targeted oncology
Volume	16
Issue number	1
Early online date	2020
DOIs	https://doi.org/10.1007/s11523-020-00769-z
Publication status	Published - Jan 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s11523-020-00769-z

Developing-symptom-lists-for-people-with-cancer-treated-with-targeted-therapies.pdfFinal published version, 593 KBLicence: CC BY

Cite this

@article{a076daab57fe417587d1bd77f4a5db5c,

title = "Developing Symptom Lists for People with Cancer Treated with Targeted Therapies",

abstract = "Background: Targeted therapies (TTs) have revolutionised cancer treatment with their enhanced specificity of action. Compared with conventional therapies, TTs are delivered over a longer period and often have unusual symptom profiles. Patient-reported outcome measures such as symptom side-effect lists need to be developed in a time-efficient manner to enable a rapid and full evaluation of new treatments and effective clinical management Objective: The aim of this study was to develop a set of TT-related symptoms and identify the optimal method for developing symptom lists. Patients and Methods: Symptoms from TT treatment in the context of Chronic Myeloid Leukaemia (CML), HER2-positive breast cancer, or Gastrointestinal Stromal Tumours (GIST) were identified through literature reviews, interviews with healthcare professionals (HCPs) and patients, and patient focus groups. The symptom set was then pilot tested in patients across the three cancer diagnoses: The number of items derived from each source (literature, patients, or HCPs) were compared. Results: A total of 316 patients and 86 HCPs from 16 countries participated. An initial set of 209 symptoms was reduced to 61 covering 12 symptom categories. Patient interviews made the greatest contribution to the item set. Conclusions: Symptom lists should be created based on input from patients. The item set described will be applicable to the assessment of new TTs, and in monitoring treatment.",

author = "Sodergren, \{Samantha C.\} and Wheelwright, \{Sally J.\} and Deborah Fitzsimmons and Fabio Efficace and Mirjam Sprangers and Peter Fayers and Amelie Harle and Heike Schmidt and Andrew Bottomley and Anne-Sophie Darlington and Charlotte Benson and Anne Bredart and Leopold Hentschel and Arraras, \{Juan Ignacio\} and Georgios Ioannidis and Michael Leahy and Iwona Lugowska and Ourania Nicolatou-Galitis and Duska Petranovic and Rohde, \{Gudrun E.\} and Vasilis Vassiliou and \{the EORTC Quality of Life Group\} and Johnson, \{Colin D.\}",

note = "Funding Information: Juan Ignacio Arraras received funding from “la Caixa” Foundation (ID 1000010434), Caja Navarra Foundation and UNED Pamplona, under agreement LCF/PR/PR15/51100007. The remaining authors declare that they have no conflicts of interest that might be relevant to the contents of this article. Publisher Copyright: {\textcopyright} 2020, Springer Nature Switzerland AG.",

year = "2021",

month = jan,

doi = "10.1007/s11523-020-00769-z",

language = "English",

volume = "16",

pages = "95--107",

journal = "Targeted oncology",

issn = "1776-2596",

publisher = "Springer Paris",

number = "1",

}

TY - JOUR

T1 - Developing Symptom Lists for People with Cancer Treated with Targeted Therapies

AU - Sodergren, Samantha C.

AU - Wheelwright, Sally J.

AU - Fitzsimmons, Deborah

AU - Efficace, Fabio

AU - Sprangers, Mirjam

AU - Fayers, Peter

AU - Harle, Amelie

AU - Schmidt, Heike

AU - Bottomley, Andrew

AU - Darlington, Anne-Sophie

AU - Benson, Charlotte

AU - Bredart, Anne

AU - Hentschel, Leopold

AU - Arraras, Juan Ignacio

AU - Ioannidis, Georgios

AU - Leahy, Michael

AU - Lugowska, Iwona

AU - Nicolatou-Galitis, Ourania

AU - Petranovic, Duska

AU - Rohde, Gudrun E.

AU - Vassiliou, Vasilis

AU - the EORTC Quality of Life Group

AU - Johnson, Colin D.

N1 - Funding Information: Juan Ignacio Arraras received funding from “la Caixa” Foundation (ID 1000010434), Caja Navarra Foundation and UNED Pamplona, under agreement LCF/PR/PR15/51100007. The remaining authors declare that they have no conflicts of interest that might be relevant to the contents of this article. Publisher Copyright: © 2020, Springer Nature Switzerland AG.

PY - 2021/1

Y1 - 2021/1

N2 - Background: Targeted therapies (TTs) have revolutionised cancer treatment with their enhanced specificity of action. Compared with conventional therapies, TTs are delivered over a longer period and often have unusual symptom profiles. Patient-reported outcome measures such as symptom side-effect lists need to be developed in a time-efficient manner to enable a rapid and full evaluation of new treatments and effective clinical management Objective: The aim of this study was to develop a set of TT-related symptoms and identify the optimal method for developing symptom lists. Patients and Methods: Symptoms from TT treatment in the context of Chronic Myeloid Leukaemia (CML), HER2-positive breast cancer, or Gastrointestinal Stromal Tumours (GIST) were identified through literature reviews, interviews with healthcare professionals (HCPs) and patients, and patient focus groups. The symptom set was then pilot tested in patients across the three cancer diagnoses: The number of items derived from each source (literature, patients, or HCPs) were compared. Results: A total of 316 patients and 86 HCPs from 16 countries participated. An initial set of 209 symptoms was reduced to 61 covering 12 symptom categories. Patient interviews made the greatest contribution to the item set. Conclusions: Symptom lists should be created based on input from patients. The item set described will be applicable to the assessment of new TTs, and in monitoring treatment.

AB - Background: Targeted therapies (TTs) have revolutionised cancer treatment with their enhanced specificity of action. Compared with conventional therapies, TTs are delivered over a longer period and often have unusual symptom profiles. Patient-reported outcome measures such as symptom side-effect lists need to be developed in a time-efficient manner to enable a rapid and full evaluation of new treatments and effective clinical management Objective: The aim of this study was to develop a set of TT-related symptoms and identify the optimal method for developing symptom lists. Patients and Methods: Symptoms from TT treatment in the context of Chronic Myeloid Leukaemia (CML), HER2-positive breast cancer, or Gastrointestinal Stromal Tumours (GIST) were identified through literature reviews, interviews with healthcare professionals (HCPs) and patients, and patient focus groups. The symptom set was then pilot tested in patients across the three cancer diagnoses: The number of items derived from each source (literature, patients, or HCPs) were compared. Results: A total of 316 patients and 86 HCPs from 16 countries participated. An initial set of 209 symptoms was reduced to 61 covering 12 symptom categories. Patient interviews made the greatest contribution to the item set. Conclusions: Symptom lists should be created based on input from patients. The item set described will be applicable to the assessment of new TTs, and in monitoring treatment.

UR - https://www.scopus.com/pages/publications/85095712720

U2 - 10.1007/s11523-020-00769-z

DO - 10.1007/s11523-020-00769-z

M3 - Article

C2 - 33165751

SN - 1776-2596

VL - 16

SP - 95

EP - 107

JO - Targeted oncology

JF - Targeted oncology

IS - 1

ER -

Developing Symptom Lists for People with Cancer Treated with Targeted Therapies

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this